Ibogaine attenuation of morphine withdrawal in mice: Role of glutamate N-methyl-D-aspartate receptors

Progress in Neuro-Psychopharmacology and Biological Psychiatry

Volumn 27, Issue 5, 2003, Pages 781-785

  Leal, Mirna Bainy ^a   Michelin, Kátia ^b   Souza, Diogo Onofre ^c   Elisabetsky, Elaine ^b  

^a PONTIFICAL CATHOLIC UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^b FEDERAL UNIVERSITY OF RIO GRANDE DO SUL   (Brazil)

^c Curso de Pos Graduacao Bioquim   (Brazil)

Author keywords

Ibogaine; Morphine withdrawal; NMDA receptor; 3H MK 801 binding

Indexed keywords

DIZOCILPINE; IBOGAINE; MORPHINE; N METHYL DEXTRO ASPARTIC ACID; N METHYL DEXTRO ASPARTIC ACID RECEPTOR; N METHYL DEXTRO ASPARTIC ACID RECEPTOR BLOCKING AGENT; NALOXONE;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BRAIN MEMBRANE; CONTROLLED STUDY; DRUG BINDING; DRUG EFFECT; DRUG MECHANISM; JUMPING; LOW DRUG DOSE; MALE; MORPHINE ADDICTION; MOUSE; NONHUMAN; PROTEIN FUNCTION; RECEPTOR BLOCKING; WITHDRAWAL SYNDROME;

EID: 0043125579     PISSN: 02785846     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0278-5846(03)00109-X     Document Type: Article

References (42)

1. Aghajanian G.K., Kogan J.H., Moghaddam B. Opiate withdrawal increases glutamate and aspartate efflux in the locus coeruleus: an in vivo microdialysis study. Brain Res. 636:1994;126-130.
2. Alper K.R., Lotsof H.S., Frenken G.M.N., Luciano D.J., Bastiaans J. Treatment of acute opioid withdrawal with ibogaine. Am. J. Addict. 8:1999;234-242.
3. Bisaga A., Popik P. In search of a new pharmacological treatment for drug and alcohol addiction: N-methyl-D-aspartate (NMDA) antagonists. Drug Alcohol Depend. 59:2000;1-15.
4. Cappendijk S.L.T., Fekkes D., Dzoljic M. The inhibitory effect of norharman on morphine withdrawal syndrome in rats: comparison with ibogaine. Behav. Brain Res. 65:1994;117-119.
5. Chen K., Kokate T.G., Donevan S.D., Carrol F.I., Rogawski M.A. Ibogaine block of the NMDA receptor: in vitro and in vivo studies. Neuropharmacology. 35:1996;423-431.
6. Dzoljic E.D., Kaplan C.D., Dzoljic M.R. Effect of ibogaine on naloxone precipitated withdrawal syndrome in chronic morphine dependent rats. Arch. Int. Pharmacodyn. 294:1988;64-70.
7. 3H] glutamate binding to fresh and frozen crude plasma membranes isolated from cerebral cortex of adults rats. Biochem. Mol. Biol. Int. 44:1998;1265-1272.
8. Frances B., Gout R., Cros J., Zajac J.M. Effects of ibogaine on naloxone-precipitated withdrawal in morphine-dependent mice. Fundam. Clin. Pharmacol. 6:1992;327-332.
9. Glick S.D., Maisonneuve I.M. Mechanisms of antiaddictive actions of ibogaine. Ann. N. Y. Acad. Sci. 844:1998;214-226.
10. Glick S.D., Rossman K., Steindorf S., Maisonneuve I.M., Carlson J.N. Effects and aftereffects of ibogaine on morphine self-administration in rats. Eur. J. Pharmacol. 195:1991;341-345.
11. Glick S.D., Rossman K., Maisonneuve I.M., Carlson J.N. Effects of ibogaine on acute signs of morphine withdrawal in rats: independence from tremor. Neuropharmacology. 31:1992;497-500.
12. 3H] MK-801 to brain regions and spinal cord of mice treated chronically with morphine. Gen. Pharmacol. 27:1996;91-94.
13. Jhamandas J.H., Harris K.H., Petron T., Jhamandas K.H. Activation of nitric oxide-synthesizing neurons during precipitated morphine withdrawal. NeuroReport. 7:1996;2843-2846.
14. Layer R.T., Skolnick P., Bertha C.M., Bandarage U.K., Kuehne M.E., Popik P. Structurally modified ibogaine analogs exhibit differing affinities for NMDA receptors. Eur. J. Pharmacol. 309:1996;159-165.
15. Leal M.B., Souza D.O.G., Elisabetsky E. Long-lasting ibogaine protection against NMDA-induced convulsions in mice. Neurochem. Res. 25:2000;1083-1087.
16. Lotsof H.S. Ibogaine in the treatment of chemical dependence disorders: clinical perspectives. MAPS. 5:1995;16-27.
17. Lowry O.H., Rosebrough N.J., Farr A.L., Randall R.J. Protein measurement with the Folin phenol reagent. J. Biol. Chem. 193:1951;265-275.
18. Mash D.C., Staley J.K., Pablo J.P., Holohean A.M., Hackman J.C., Davidoff R.A. Properties of ibogaine and its principal metabolite (12-hydroxyibogamine) at the MK-801 binding site of the NMDA receptor complex. Neurosci. Lett. 192:1995;53-56.
19. Mash D.C., Kovera C.A., Buck B.E., Norenberg M.D., Shapshak P., Hearn W.L., Sanchez-Ramos J. Medication development of ibogaine as a pharmacotherapy for drug dependence. Ann. N. Y. Acad. Sci. 844:1998;274-292.
20. Nestler E.J., Aghajanian G.K. Molecular and cellular basis of addiction. Science. 278:1997;58-63.
21. Ozawa S., Kamiya H., Tsukuki K. Glutamate receptors in the mammalian central nervous system. Prog. Neurobiol. 54:1998;581-618.
22. Parker L.A., Burton P., Mcdonald R.V., Kim J.Á., Siegel S. Ibogaine interferes with motivational and somatic effects of naloxone-precipitated withdrawal from acutely administered morphine. Prog. Neuro-Psychopharmacol. Biol. Psychiatry. 26:2002;293-297.
23. 3H]MK-801 binding to the NMDA receptor complex, and its modulation in humans frontal cortex during development and aging. Brain Res. 588:1992;277-286.
24. Popik P., Danysz W. Inhibition of reinforcing effects of morphine and motivational aspects of naloxone-precipitated opioid withdrawal by N-methyl-D-aspartate receptor antagonist, memantine. J. Pharmacol. Exp. Ther. 280:1997;854-865.
25. Popik P., Skolnick P. The NMDA antagonist memantine blocks the expression and maintenance of morphine dependence. Pharmacol. Biochem. Behav. 53:1996;791-797.
26. 3H]MK-801 binding to the NMDA receptor complex. Psychopharmacology. 114:1994;672-674.
27. Popik P., Layer R.T., Fossom L.H., Benveniste M., Geter-Douglass B., Witkin J.M., Skolnick P. NMDA antagonist properties of the putative anti-addictive drug, ibogaine. J. Pharmacol. Exp. Ther. 275:1995;753-760.
28. Popik P., Layer R.T., Skolnick P. 100 years of ibogaine: neurochemical and pharmacological actions of a putative anti-addictive drug. Pharmacol. Rev. 47:1995;235-253.
29. Popik P., Mamczarz J., Fraczek M., Widla G., Hesselink M., Danysz W. Inhibition of reinforcing effects of morphine and naloxone-precipitated opioid withdrawal by novel glycine site and uncompetitive NMDA receptor antagonists. Neuropharmacology. 37:1998;1033-1042.
30. Ripley T.L., Little H.J. Ethanol withdrawal hyperexcitability in vitro is selectively decreased by a competitive NMDA receptor antagonist. Brain Res. 699:1995;1-11.
31. Rosseti Z.L., Carboni S. Ethanol withdrawal is associated with increased extracellular glutamate in the rat striatum. Eur. J. Pharmacol. 283:1995;177-183.
32. Sharpe L.G., Jaffe J.H. Ibogaine fails to reduce naloxone-precipitated withdrawal in the morphine-dependent rat. NeuroReport. 1:1990;17-19.
33. Sisko B. Interrupting drug dependency with ibogaine: a summary of four case histories. MAPS. 4:1993;15-23.
34. Staley J.K., Ouyang Q., Pablo J., Hearn W.L., Flynn D.D., Rothman R.B., Rice K.C., Mash D.C. Pharmacological screen for activities of 12-hydroxyibogamine: a primary metabolite of the indole alkaloid ibogaine. Psychopharmacology. 127:1996;10-18.
35. Sweetnam P.M., Lancaster J., Snowman A., Collins J.L., Perschke S., Bauer C., Ferkany J. Receptor binding profile suggests multiple mechanisms of action are responsible for ibogaine's putative anti-addictive activity. Psychopharmacology. 118:1995;369-376.
36. Tokuyama S., Ho I.K. Inhibitory effect of diltiazem, an L-type Ca2+ channel blocker, on naloxone-induced glutamate levels in the locus coeruleus of opioid-dependent rats. Brain Res. 722:1996;212-216.
37. Tokuyama S., Hiroyuki W., Ho I.K. Direct evidence for a role of glutamate in the expression of the opioid withdrawal syndrome. Eur. J. Pharmacol. 295:1996;123-129.
38. Tokuyama S., Zhu H., Oh S., Ho I.K., Yamamoto T. Further evidence for a role of NMDA receptors in the locus coeruleus in the expression of withdrawal syndrome from opioids. Neurochem. Int. 39:2001;103-109.
39. Trujillo K.A., Akil H. Inhibition of morphine tolerance and dependence by the NMDA receptor antagonist MK-801. Science. 251:1991;85-87.
40. Wolf K. Addiction medicine. Karkh J. Drug Abuse Handbook. 1998;500-513 CRC Press, San Francisco, CA.
41. Zarridast M.-R., Farzin D. Nicotine attenuates naloxone-induced jumping behavior in morphine-dependent mice. Eur. J. Pharmacol. 298:1996;1-6.
42. Zhu H., Barr G.A. Opiate withdrawal during development: are NMDA receptors indispensable? Trends Pharmacol. Sci. 22:2001;404-408.